740 related articles for article (PubMed ID: 33858437)
1. mRNA therapeutics in cancer immunotherapy.
Beck JD; Reidenbach D; Salomon N; Sahin U; Türeci Ö; Vormehr M; Kranz LM
Mol Cancer; 2021 Apr; 20(1):69. PubMed ID: 33858437
[TBL] [Abstract][Full Text] [Related]
2. mRNA Cancer Vaccines.
Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunological effects of mRNA vaccines in malignant diseases.
Heine A; Juranek S; Brossart P
Mol Cancer; 2021 Mar; 20(1):52. PubMed ID: 33722265
[TBL] [Abstract][Full Text] [Related]
4. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination.
Sun X; Zeng L; Huang Y
J Gene Med; 2019 Jul; 21(7):e3089. PubMed ID: 30958606
[TBL] [Abstract][Full Text] [Related]
5. mRNA-based dendritic cell vaccines.
Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
[TBL] [Abstract][Full Text] [Related]
6. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
7. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
Ramachandran M; Dimberg A; Essand M
Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
[TBL] [Abstract][Full Text] [Related]
8. The ReNAissanCe of mRNA-based cancer therapy.
Van Lint S; Renmans D; Broos K; Dewitte H; Lentacker I; Heirman C; Breckpot K; Thielemans K
Expert Rev Vaccines; 2015 Feb; 14(2):235-51. PubMed ID: 25263094
[TBL] [Abstract][Full Text] [Related]
9. When transgenes shape immunity: cancer immune-gene therapy.
Bonini C; Parmiani G
J Gene Med; 2012 Jun; 14(6):384-5. PubMed ID: 22736622
[No Abstract] [Full Text] [Related]
10. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
[TBL] [Abstract][Full Text] [Related]
11. RNA-Based Vaccines in Cancer Immunotherapy.
McNamara MA; Nair SK; Holl EK
J Immunol Res; 2015; 2015():794528. PubMed ID: 26665011
[TBL] [Abstract][Full Text] [Related]
12. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.
Kalady MF; Onaitis MW; Padilla KM; Emani S; Tyler DS; Pruitt SK
J Surg Res; 2002 Jun; 105(1):17-24. PubMed ID: 12069496
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells.
Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V
J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987
[TBL] [Abstract][Full Text] [Related]
14. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.
Haabeth OAW; Blake TR; McKinlay CJ; Waymouth RM; Wender PA; Levy R
Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9153-E9161. PubMed ID: 30201728
[TBL] [Abstract][Full Text] [Related]
15. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
17. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
[TBL] [Abstract][Full Text] [Related]
18. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
19. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
20. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]